7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
Newly designed proteins can effectively degrade specific proteins in cells, offering a potential new therapy method.
2 citations
,
November 1996 in “Transplantation” Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.
7 citations
,
September 2006 in “Clinical lymphoma & myeloma” Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.
June 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Neutropenic patients show significant changes in immune cell types and lower neutrophil and natural killer cell percentages.
1 citations
,
July 2025 in “Frontiers in Endocrinology” ApoBDs, once seen as waste, are now viewed as potential tools for disease treatment and tissue repair.
April 2019 in “Journal of Investigative Dermatology” Blocking LFA-1 prevents hair loss in mice.
1 citations
,
August 1983 in “PubMed” CVP therapy showed moderate success in treating advanced non-Hodgkin's lymphoma, but more intensive treatment is needed for better outcomes.
March 2022 in “Journal of Investigative Dermatology” Discoid Lupus Erythematosus causes scalp plaques that can lead to hair loss, and antimalarial drugs are effective treatments.
ILC1-like cells may contribute to hair loss in alopecia areata and could be new treatment targets.
14 citations
,
November 2016 in “Lupus” Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.
278 citations
,
March 2013 in “Gut” Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.
9 citations
,
September 2009 in “PubMed” Antigen presenting cells around hair follicles are crucial in SLE-related hair loss.
May 2025 in “Frontiers in Immunology” Autoimmune diseases with high tissue recovery often relapse and remit, while those with low recovery rarely remit.
June 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Children with frequent severe infections and low antibodies should be checked for immune deficiencies.
Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.
9 citations
,
August 2024 in “Pharmacological Reviews” The intestinal lymphatic system is active and promising for targeted drug delivery and therapies.
1 citations
,
January 2026 in “International Journal of Dermatology” Dupilumab can cause unexpected scalp issues, so early symptom recognition is important to avoid hair loss.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
2 citations
,
July 2007 in “Cancer biology & therapy” Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
1 citations
,
April 2016 in “Journal of Investigative Dermatology” Targeting specific T cells may help treat alopecia areata.
37 citations
,
September 2008 in “The American journal of surgical pathology” Hair follicle hyperplasia is common in both benign and malignant skin lymphoproliferative disorders, with a proposed new term "pseudolymphomatous adnexitis."
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” The study suggests that a specific type of immune cell, memory-like NK cells, may increase during active hair loss in Alopecia areata.
October 2021 in “European journal of cancer” Repeated biopsies are crucial for managing lupus panniculitis when initial treatments fail.
January 1994 in “Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics” Both VEPA and ML-Y1 treatments are not effective enough for elderly non-Hodgkin's lymphoma patients.
March 2026 in “Skin Appendage Disorders” Belatacept may be a promising treatment for alopecia areata.
16 citations
,
July 2002 in “Australasian Journal of Dermatology” A woman with lupus experienced skin death due to a blood clotting disorder after stopping a blood thinner, which healed with treatment.
5 citations
,
February 2024 in “Journal of Investigative Dermatology” Alopecia areata patients have fewer protective regulatory B cells, which may contribute to the disease.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
1 citations
,
November 1991 in “PubMed” Immunoadsorption successfully treated a man's resistant polymyositis.